PDSB News and Press, PDS Biotechnology Corporation From 01/08/23

Summary Over the last 18 months, PDS Biotechnology has continued producing some good data in HPV-associated cancers. However, I am a little perplexed by their finances. I will continue to watch this stock. PDS Biotech ( PDSB ) uses its Versammune platform combined with...

PDS Biotechnology ( NASDAQ: PDSB ) is down 14% in late Tuesday trading after the company l icensed a cancer drug candidate from Merck KGaA ( OTCPK:MKGAF ). Under the deal, Merck KGaA ( OTCPK:MKKGY ) will receive an upfront payment of $5M, up to $11 million in...

PDS Biotechnology ( NASDAQ: PDSB ) said it signed a licensing agreement with Merck KGaA ( OTCPK:MKGAF ) ( OTCPK:MKKGY ) for tumor drug candidate M9241 (formerly known as NHS-IL12), which will join the pipeline as PDS0301. Under the agreement, PDS Biotech will receive from Merc...

PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune® platform PDS Biotech to host conference call and webcast on Tuesday, January 3, 2023, at 8:00 AM EST FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotec...

PDS Biotechnology ( NASDAQ: PDSB ) is up 3% in premarket trading on results on the company's triple combination therapy for human papillomavirus (HPV)-positive cancers. The triple combination includes the company's PDS0101, the tumor-targeting IL-12 fusion protein M9241, and bintr...

FLORHAM PARK, N.J., Dec. 28, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced expanded interim data in a Phase 2 clinical trial...

FLORHAM PARK, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced the completion of enrollment in the first sta...

NEW YORK, NY / ACCESSWIRE / December 5, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with PDS Biotechnology Corporation. Toni had the pleasure of recentl...

Chief Medical Officer, Dr. Lauren V. Wood, to present on the development of targeted immunotherapies for solid tumors based on the Versamune ® platform Dr. Siva Gandhapudi, Director of Immunology Product Development, to present on development of a universal flu vaccine ...

PDS Biotechnology Corporation (PDSB) Q3 2022 Results Conference Call November 14, 2022 08:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Matt Hil...